For our immune system to contain or eliminate malignant solid tumours, both myeloid and
lymphoid haematopoietic cells must not only extravasate from the bloodstream into the …

During the past 40 years, cytokines and cytokine receptors have been extensively
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …

Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …

Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Decades of research have established atherosclerosis as an inflammatory disease. Only
recently though, clinical trials provided proof-of-concept evidence for the efficacy of anti …

Primary cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphomas
that present in the skin with no evidence of extracutaneous disease at the time of diagnosis …

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown
antitumor activity in estrogen receptor-positive (ER+) breast cancer preclinical models. PF …

Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA
modification, histone modification, RNA modification, chromatin remodeling, and non-coding …